[Clinical trial with glypentide. Comparison with the hypoglycemic activity of other sulfonylurea compounds].
In 53 sulphonylurea-treated diabetic patients, the activity of glypentide and the patients' general tolerance of the drug were studied. The results show that the new oral hypoglycemic drug has a similar, and superior in many instances, activity to other similar drugs such as glybenclamide and glypizide, and to the activity of the classical sulphonylureas (chlorpropamide and carbutamide). The patients' tolerance of the drug was excellent. No digestive disorders, undesirable side effects or hypoglycemias were seen in the patients. Analysis of lipid levels showed that glypentide induces a significant decrease in total lipid and cholesterol values, being this action more marked in patients with normal body weight non-treated with a hypocaloric diet.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003517:Cyclopentanes / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*
D001549:Benzamides; D003517:Cyclopentanes; D013453:Sulfonylurea Compounds
Ensayo clínico con glipentida. Comparación con la actividad hipoglucemiante de otras sulfonilureas